SCHEMBL6539246

SCHEMBL6539246

CC(C)CCOc1ccc(C(=O)O)c(Cc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.52
NR1H4 Q96RI1 2/20 0.47
LTB4R Q15722 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
RARB P10826 1/20 0.44
PPARG P37231 3/20 0.44
PPARD Q03181 2/20 0.44
PPARA Q07869 2/20 0.44
EPHX2 P34913 1/20 0.44
PTPN11 Q06124 1/20 0.43
HTT P42858 1/20 0.43
S1PR1 P21453 1/20 0.43
S1PR5 Q9H228 1/20 0.43
MCL1 Q07820 2/20 0.42
BCL2L11 O43521 1/20 0.42
BCL2L1 Q07817 1/20 0.42
BAK1 Q16611 1/20 0.42
PTGES O14684 1/20 0.42
ALOX5 P09917 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10493530 0.88 LTB4R (0.49) LTB4RLTB4R2PTPN11MCL1ALDH1A1
SCHEMBL9328907 0.82 LTB4R (0.49) LTB4RLTB4R2MAOB
SCHEMBL542829 0.81 LTB4R (0.60) LTB4RLTB4R2MCL1ALOX5KDM4E
SCHEMBL5648170 0.80 MAPK1 (0.59) MAPK1NR1H4RARBEPHX2HTT
SCHEMBL3098374 0.79 MTNR1A (0.58) MAPK1HTTALDH1A1PTPN2PTPN1
SCHEMBL6538645 0.79 LTB4R (0.47) LTB4RLTB4R2PTPN11MCL1KDM4E
SCHEMBL22976873 0.77 TSHR (0.45) MAPK1LTB4RLTB4R2KDM4EMAOB
SCHEMBL11566902 0.76 MAOB (0.53) MAPK1ALOX5ALDH1A1HSD17B10MAOB
SCHEMBL13162905 0.75 MAPK1 (0.60) MAPK1NR1H4RARBPPARGPPARA
SCHEMBL2834568 0.74 KDM4E (0.54) LTB4RLTB4R2PPARGKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB MAPK1 1483/4885NR1H4 42/4885LTB4R 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.